Ericsson, Inc. v. D-Link Systems, Inc.’s Empirical Analysis
773 F.3d 1201 · 2014
Citation profile
26 federal appellate · 11 district ·
How this case has been cited
Cited by 75 later decisions — most recently December 2024 · most notably Finjan, Inc. v. Blue Coat Systems, Inc. (2018), Carnegie Mellon University v. Marvell Technology Group, Ltd. (2015)
26 federal appellate · 11 district ·
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Applies 28 U.S.C. § 1295 · 35 U.S.C. § 271 · 35 U.S.C. § 281 · 35 U.S.C. § 284
Relies on Daubert v. Merrell Dow Pharmaceuticals, Inc. · United States v. Socony-Vacuum Oil Co. · Griffin v. United States · Phillips v. AWH Corp. · Dowagiac Manufacturing Company v. Minnesota Moline Plow Company No 6 Dowagiac Manufacturing Company
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 75 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“[W]here multi-component products are involved, the governing rule is that the ultimate combination of royalty base and royalty rate must reflect the value attributable to the infringing features of the product, and no more.”
3 later decisions quote this exact passage · from the majority“must in every case give evidence tending to separate or apportion the defendant's profits and the patentee's damages between the patented feature and the unpatented features.”
3 later decisions quote this exact passage · from the majority“by adjustment of the royalty rate so as to discount the value of a product's non-patented features.”
3 later decisions quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.